Last updated on August 2014

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ® (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors


Brief description of study

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ® (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Detailed Study Description

A study to evaluate the effect of long-term treatment with Belviq® (Lorcaserin HCI) on the incidence of major adverse cardiovascular events and conversion to Type 2 Diabetes Mellitus in obese and overweight subjects with cardiovascular disease or multiple cardiovascular risk factors.

Half of the patients will be randomly assigned to receive Belviq® 10 mg twice daily and half of the patients will be assigned to a matching placebo. All patients will be on a reduced-calorie, increased physical activity program and participate in a Healthy Lifestyles Program which includes access to a nutritionist as well as online diet and exercise resources.

Clinical Study Identifier: TX139056

Contact Investigators or Research Sites near you

Start Over

Wendy Schneider, MSN, RN, CCRC

Holy Cross Jim Moran Heart and Vascular Research Institute
Coral Springs, FL USA
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.